Happy National Nurses Month! ๐
To the front-line nurses who show up every day with compassion, resilience, and unwavering dedication - thank you! From chronic disease management and early detection to care coordination, practice operations, and patient support, nurses are at the center of healthcare.
At AEYE Health, weโre proud to support care teams with a solution that seamlessly integrates diabetic retinopathy screening into everyday visits, making it easier to deliver preventive care, close gaps, and protect patientโs vision.
Your impact extends across the entire patient journey, and goes far beyond what can be measured. Thank you for your commitment to elevating patient care every single day!
#NationalNursesMonth #PrimaryCare #DiabeticRetinopathy #PreventiveHealth
๐๐๐ฎ๐ฟ๐ฒ๐ป๐ฒ๐๐ ๐ถ๐ ๐ด๐ฟ๐ฒ๐ฎ๐. ๐๐ฐ๐ฐ๐ฒ๐๐ ๐ถ๐ ๐ฏ๐ฒ๐๐๐ฒ๐ฟ.
This Healthy Vision Month, weโre looking past patient-facing campaigns to a harder truth: The bottleneck in diabetic eye care isn't a lack of awareness- it's structural friction
Despite clear guidelines, 60% of patients still miss their annual screenings. Traditional referral loops and high "ungradable" rates in teleretinal programs create a persistent blind spot in population health.
The shift toward Point-of-Care: As highlighted in the 2026 ADA Standards of Care, moving screening into the primary care setting is the only way to optimize the "last mile" of delivery.
This is where AI is becoming a core infrastructure layer in diabetic eye care, enabling scalable population health through immediate screening in primary care and real-time detection of referable disease. It reduces reliance on specialists and replaces referral-based bottlenecks with point-of-care delivery.
Thatโs why more health systems are moving diabetic eye screening into primary care.
With AEYE-DS, our autonomous AI diabetic retinopathy solution, providers can evaluate patients during routine visits and receive immediate results. As the only FDA-cleared solution compatible with a portable camera, AEYE-DS enables true point-of-care deployment with just one image per eye in under a minute, making diabetic eye screening a seamless part of routine workflows.
As healthcare continues shifting toward value-based care, the question isnโt whether this matters. Itโs whether our workflows make it easy enough to happen consistently. Healthy Vision Month highlights the importance of aligning infrastructure with real-world patient needs and the role of AI-enabled solutions in making that alignment possible.
๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ณ๐๐น๐น ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ ๐๐ผ ๐ฒ๐ ๐ฝ๐น๐ผ๐ฟ๐ฒ ๐ต๐ผ๐ ๐๐ผ๐ฟ๐ธ๐ณ๐น๐ผ๐ ๐ฎ๐ป๐ฑ ๐ถ๐ป๐ณ๐ฟ๐ฎ๐๐๐ฟ๐๐ฐ๐๐๐ฟ๐ฒ ๐ฐ๐ฎ๐ป ๐ถ๐บ๐ฝ๐ฟ๐ผ๐๐ฒ ๐ฑ๐ถ๐ฎ๐ฏ๐ฒ๐๐ถ๐ฐ ๐ฒ๐๐ฒ ๐๐ฐ๐ฟ๐ฒ๐ฒ๐ป๐ถ๐ป๐ด ๐ฎ๐ ๐๐ฐ๐ฎ๐น๐ฒ:ย https://t.co/LPXqxPw7nk
#HealthyVisionMonth #PopulationHealth #DiabetesCare #DiabeticRetinopathy #PrimaryCare #ValueBasedCare
๐ฆ๐๐ฐ๐ฐ๐ฒ๐๐ ๐ถ๐ป ๐ต๐ฒ๐ฎ๐น๐๐ต๐ฐ๐ฎ๐ฟ๐ฒ ๐๐๐ฎ๐ฟ๐๐ ๐๐ถ๐๐ต ๐ฎ ๐๐ต๐ฎ๐ฟ๐ฒ๐ฑ ๐๐ถ๐๐ถ๐ผ๐ป. ๐๏ธ
Last week, our sales team gathered at our New York City office for an intensive 2-day planning session.
We werenโt just talking numbers; we were aligning on our 2026 roadmap to better support providers in closing the gap in diabetic retinopathy screening.
Our mission remains clear: to eliminate preventable vision loss by removing barriers to diabetic eye care and ensuring AEYE-DS is seamlessly integrated into every patient visit.
Beyond the strategy sessions, we also stepped into the kitchen for a team cooking workshop๐ฅ. It was a great way to recharge and a reminder that while our AI is autonomous, our success is built on the people.
#TeamWork #SalesTeam #NYC #GoToMarket
๐๐๐ ๐ฎ๐ฌ๐ฎ๐ฒ ๐ฆ๐๐ฎ๐ป๐ฑ๐ฎ๐ฟ๐ฑ๐ ๐ผ๐ณ ๐๐ฎ๐ฟ๐ฒ: ๐ง๐ต๐ฒ ๐ข๐ณ๐ณ๐ถ๐ฐ๐ถ๐ฎ๐น ๐ฆ๐ต๐ถ๐ณ๐ ๐๐ผ ๐๐๐๐ผ๐ป๐ผ๐บ๐ผ๐๐ ๐๐ ๐ถ๐ป ๐ฃ๐ฟ๐ถ๐บ๐ฎ๐ฟ๐ ๐๐ฎ๐ฟ๐ฒ
The release of the American Diabetes Association's (ADA) 2026 Standards of Care in Diabetes represents more than a clinical update; it is a structural transformation in the delivery of diabetic eye care.
For years, the referral-based models for diabetic retinopathy screening have struggled to close the care gap: the long wait time and fragmented workflows mean the vast majority of patients miss their essential annual screenings.
AEYE-DS closes the diabetic eye care gap by bringing screening directly to the point of care. With the ADA guidelines now recognizing autonomous AI as a leading standard for primary care, AEYE-DS transforms vision preservation into a seamless, accessible part of every routine visit.
๐๐๐ฌ๐-๐๐ฆ: ๐ฅ๐ฒ๐ฐ๐ผ๐ด๐ป๐ถ๐๐ฒ๐ฑ ๐ฎ๐ ๐๐ต๐ฒ ๐ก๐ฒ๐ ๐ฆ๐๐ฎ๐ป๐ฑ๐ฎ๐ฟ๐ฑ
Recognized within the highest tier of clinical validation, AEYE-DS fulfills the ADAโs goal of bringing vision-saving screening to where itโs needed most, in primary care:
โฌฅ๐ฃ๐ผ๐ฟ๐๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ ๐ฎ๐ป๐ฑ ๐จ๐๐ฎ๐ฏ๐ถ๐น๐ถ๐๐: As the only FDA-cleared AI for portable cameras and only AI that requires just 1 image per-eye for the analysis and no dilation, AEYE-DS delivers the fast, accessible, point-of-care diagnosis the 2026 ADA Standards now demand.
โฌฅ๐๐บ๐บ๐ฒ๐ฑ๐ถ๐ฎ๐๐ฒ ๐ฅ๐ฒ๐๐๐น๐๐: AEYE-DS delivers an autonomous diagnosis at the point of care, eliminating the need for physician interpretation, and ensuring patients are successfully screened and notified of their result during the same visit.
โฌฅ>๐ต๐ต% ๐๐บ๐ฎ๐ด๐ฒ๐ฎ๐ฏ๐ถ๐น๐ถ๐๐: A superior "success rate" that ensures virtually every patient can be screened successfully before they leave the clinic.
โฌฅ๐ข๐ฝ๐ฒ๐ฟ๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ณ๐ณ๐ถ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐: Autonomous AI manages routine diagnostics, allowing specialists to focus on treatment while seamless EHR integration automates everything - documentation, billing, care cap closure coding and even referral triggers for the patients found positive for referable DR.
โฌฅ๐ฉ๐ฒ๐ฟ๐ถ๐ณ๐ถ๐ฒ๐ฑ ๐ฅ๐ฒ๐ถ๐บ๐ฏ๐๐ฟ๐๐ฒ๐บ๐ฒ๐ป๐: Fully reimbursable under CPT 92229, finally enabling financial viability of AI-based screening.
By adopting AEYE-DS, providers can move beyond the โreferral black holeโ and deliver the new gold standard in vision preservation.
๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ณ๐๐น๐น ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ ๐๐ผ ๐๐ฒ๐ฒ ๐ต๐ผ๐ ๐๐ ๐๐ฐ๐ฟ๐ฒ๐ฒ๐ป๐ถ๐ป๐ด ๐ถ๐ ๐ฟ๐ฒ๐ฑ๐ฒ๐ณ๐ถ๐ป๐ถ๐ป๐ด ๐ฑ๐ถ๐ฎ๐ฏ๐ฒ๐๐ถ๐ฐ ๐ฒ๐๐ฒ ๐ฐ๐ฎ๐ฟ๐ฒ: https://t.co/hNfgnHdchm
๐ง๐ต๐ฟ๐ฒ๐ฒ ๐ฐ๐ถ๐๐ถ๐ฒ๐. ๐ข๐ป๐ฒ ๐ด๐ผ๐ฎ๐น: ๐๐น๐ผ๐๐ถ๐ป๐ด ๐๐ต๐ฒ ๐ฑ๐ถ๐ฎ๐ฏ๐ฒ๐๐ถ๐ฐ ๐ฒ๐๐ฒ ๐ฒ๐ ๐ฎ๐บ ๐ฐ๐ฎ๐ฟ๐ฒ ๐ด๐ฎ๐ฝ.
This April we had the privilege of joining the C. Frank Webber Lectureship and Interim Session hosted by the @TXFamilyDocs - the Texas Academy of Family Physicians, Ignite, the Florida Academy of Family Physicians (FAFP) flagship spring forum, and the American Medical Group Association (AMGA) 2026 Annual Conference.
Each event had its own focus, but one question united every leader we met: How do we close the diabetic eye exam care gap?
There is a growing realization that the current referral-heavy model to eye specialists does not achieve high enough adherence and creates a real barrier to care, as the vast majority donโt follow through. This realization has led to a shared commitment to ensuring no patient loses their sight due to a preventable gap.
It was especially exciting to see strong interest and engagement around AEYE-DS, our FDA-cleared solution that is now the fastest-growing solution in America. A fully autonomous AI diabetic retinopathy screening solution that can be performed anywhere, in under a minute, using just one image per eye to deliver on-the-spot results at the point of care.
Enabling immediate diagnosis helps enable more efficient, point-of-care workflows and helps bring advanced care directly into everyday clinical practice.
Weโre grateful for the opportunity to connect, share, and learn from so many forward-thinking clinicians and healthcare leaders who are committed to improving patient outcomes.
Primary care is at a breaking point. Between the mounting pressure to deliver earlier interventions and the struggle to manage expanding patient panels, "closing care gaps" often feels like a moving target, especially for diabetic retinopathy.
Traditionally, screening requires external referrals and separate specialist visits, resulting in low patient follow-through. For health systems, this friction creates persistent care gaps, lower HEDIS scores, and leads to the most frustrating outcome of all: preventable vision loss.
๐ง๐ต๐ฎ๐โ๐ ๐๐ต๐ ๐๐ฒโ๐ฟ๐ฒ ๐ฎ๐๐๐ฒ๐ป๐ฑ๐ถ๐ป๐ด ๐๐ต๐ฒ ๐๐ ๐๐ ๐ฎ๐ฌ๐ฎ๐ฒ ๐๐ป๐ป๐๐ฎ๐น ๐๐ผ๐ป๐ณ๐ฒ๐ฟ๐ฒ๐ป๐ฐ๐ฒ.
AMGA brings together leaders from integrated health systems and medical groups who are actively shaping the future of value-based care, population health, clinical transformation, and multispecialty integration. We are joining this conversation to help health systems move from "managing" gaps to eliminating them through autonomous AI.
If you plan to attend, weโd love to connect and demonstrate how AEYE-DS is revolutionizing the standard of care. Our FDA-cleared, fully autonomous AI enables you to close care gaps instantly by delivering a 1-minute diabetic retinopathy diagnosis on the spot - all from a single image per eye. By integrating directly into your EHR, AEYE-DS eliminates administrative friction, maximizes HEDIS scores, and allows you to capture CPT 92229 revenue right at the point of care.
Letโs discuss how we can turn a complex referral process into a seamless, one-minute clinical victory for your providers and patients
Click the link to book a meeting at the event:
https://t.co/Vu4YxwUWhf
๐ Las Vegas, NV | April 15โ18, 2026
Youโre doing the right thing by referring patients for diabetic eye exams - but too many never make it to that appointment.
If youโre attending ๐๐ด๐ป๐ถ๐๐ฒ, the ๐๐น๐ผ๐ฟ๐ถ๐ฑ๐ฎ ๐๐ฐ๐ฎ๐ฑ๐ฒ๐บ๐ ๐ผ๐ณ ๐๐ฎ๐บ๐ถ๐น๐ ๐ฃ๐ต๐๐๐ถ๐ฐ๐ถ๐ฎ๐ป๐ (๐๐๐๐ฃ) flagship spring forum, thereโs a better way to ensure your patients actually get screened!
AEYE-DS brings AI diabetic eye exams directly into your visit, delivering a complete, fully autonomous diagnostic result within seconds - before the patient walks out the door.
Close the diabetic eye care gap with no physician interpretation, just immediate diagnosis at the point of care.
As the only FDA-cleared autonomous AI designed for use with a portable camera - and the only AI that requires just one image per eye - it fits seamlessly into real-world primary care workflows.
If youโre attending Ignite, weโd love to connect and explore how AEYE-DS can bring point-of-care diabetic screening directly into your practice.
Visit our booth or schedule a time to meet with our team:
https://t.co/e3lMTRkBOK
See you there!
๐ Orlando, FL | April 17-19, 2026
๐๐ถ๐ฎ๐ฏ๐ฒ๐๐ถ๐ฐ ๐ฟ๐ฒ๐๐ถ๐ป๐ผ๐ฝ๐ฎ๐๐ต๐ ๐ฟ๐ฒ๐บ๐ฎ๐ถ๐ป๐ ๐๐ต๐ฒ ๐น๐ฒ๐ฎ๐ฑ๐ถ๐ป๐ด ๐ฐ๐ฎ๐๐๐ฒ ๐ผ๐ณ ๐ฝ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฎ๐ฏ๐น๐ฒ ๐๐ถ๐๐ถ๐ผ๐ป ๐น๐ผ๐๐ - ๐๐ฒ๐ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป๐ ๐ผ๐ณ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐๐๐ถ๐น๐น ๐บ๐ถ๐๐ ๐๐ต๐ฒ๐ถ๐ฟ ๐ฎ๐ป๐ป๐๐ฎ๐น ๐๐ฐ๐ฟ๐ฒ๐ฒ๐ป๐ถ๐ป๐ด.
Not due to lack of awareness, but due to workflow.
The challenge is not clinical knowledge - it is operational execution.
Too many steps. Too many handoffs.
Too many missed opportunities.
Traditional screening depends on external referrals, additional appointments, and disconnected coordination between primary care and eye care. The result is a โspecialist bottleneckโ that delays diagnosis and leaves the care gap wide open.
By embedding AI screening directly into the patientโs charts, screening becomes part of routine clinical workflow rather than a separate process.
AEYE-DS transforms the process by embedding FDA-cleared autonomous AI technology directly into the patientโs chart. Screening becomes part of the routine visit, not a separate hurdle.
When AEYE-DS integrates into Epic and other major EHRs, a complex referral process becomes a seamless 1-minute exam. This rapid screening requires just one image per eye and produces instant diagnostic results at the point of care. Every step is automated, from documentation in the patient chart, triggering instant referrals when required, and CPT 92229 billing - enabling care gap closure and HEDIS measure improvement.
๐ฅ๐ฒ๐ฎ๐ฑ ๐ต๐ผ๐ ๐๐ผ ๐บ๐ผ๐๐ฒ ๐ณ๐ฟ๐ผ๐บ ๐ฏ๐ผ๐๐๐น๐ฒ๐ป๐ฒ๐ฐ๐ธ ๐๐ผ ๐ฏ๐ฒ๐ป๐ฐ๐ต๐บ๐ฎ๐ฟ๐ธ: https://t.co/Pds9LnkBWI
Your diabetic patients are leaving your office without a retinopathy screen. Most won't complete that external referral.
If youโre attending the ๐. ๐๐ฟ๐ฎ๐ป๐ธ ๐ช๐ฒ๐ฏ๐ฏ๐ฒ๐ฟ ๐๐ฒ๐ฐ๐๐๐ฟ๐ฒ๐๐ต๐ถ๐ฝ ๐ฎ๐ป๐ฑ ๐๐ป๐๐ฒ๐ฟ๐ถ๐บ ๐ฆ๐ฒ๐๐๐ถ๐ผ๐ป ๐ต๐ผ๐๐๐ฒ๐ฑ ๐ฏ๐ ๐๐ต๐ฒ @TXFamilyDocs - ๐ง๐ต๐ฒ ๐ง๐ฒ๐ ๐ฎ๐ ๐๐ฐ๐ฎ๐ฑ๐ฒ๐บ๐ ๐ผ๐ณ ๐๐ฎ๐บ๐ถ๐น๐ ๐ฃ๐ต๐๐๐ถ๐ฐ๐ถ๐ฎ๐ป๐, we have a solution to close that gap right in your office.
AEYE-DS integrates directly into the primary care visit, completing the exam in just 1-minute, before the patient leaves โ eliminating the risk of yet another missed referral.
As the only FDA-cleared autonomous AI solution for a portable camera, and the only AI that requires just one image per eye for analysis, it delivers instant diagnostic results at the point of care!
Attending the TAFP meeting? Let's chat about integrating AI into your practice.
Book your meeting with us here:
https://t.co/T9uDoXKUpM
See you there
๐Round Rock, TX | April 10โ11, 2026
๐จ ๐ง๐ผ๐ฑ๐ฎ๐ ๐ถ๐ ๐ก๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ถ๐ฎ๐ฏ๐ฒ๐๐ฒ๐ ๐๐น๐ฒ๐ฟ๐ ๐๐ฎ๐
The annual wake-up call from the American Diabetes Association (ADA), serves as a reminder about the growing impact of diabetes - and the importance of early detection and proactive care.
The statistics are a call to action:
โฆ ๐ญ๐ญ๐ฑ๐ + people are living with prediabetes and are at high risk of developing diabetes.
โฆ ๐ญ.๐ฑ๐ people are diagnosed with diabetes every year.
โฆ ๐ญ ๐ถ๐ป ๐ฐย adults with diabetes doesnโt know they have it.
The ADA encourages everyone to take their quick, 1-minute Diabetes Risk Test , because understanding your risk is the first step toward prevention.
In that same spirit, we believe screening for Diabetes complications like diabetic retinopathy, the leading cause of preventable vision loss in the US should be just as practical.
At AEYE Health, we know that early detection through point-of-care screening is critical to protecting patientsโ vision before complications occur. Thatโs why we developed AEYE-DS, a 1-minute AI screening designed to make protecting a patient's sight as instant as the risk test itself. Thatโs why we developed AEYE-DS, a 1-minute AI screening designed to protect a patient's sight as instant as the risk test itself.
Take 1 minute for your health today, and please encourage your loved ones to do the same.
๐ง๐ฎ๐ธ๐ฒ ๐๐ต๐ฒ ๐๐๐ ๐ฅ๐ถ๐๐ธ ๐ง๐ฒ๐๐: https://t.co/AfT7LDXh62
๐ฆ๐ฒ๐ฒ ๐ต๐ผ๐ ๐๐ ๐ถ๐ ๐๐ฎ๐๐ถ๐ป๐ด ๐๐ถ๐๐ถ๐ผ๐ป: https://t.co/5AZNDzGN69
hashtag#DiabetesAlertDay hashtag#DiabetesAwareness hashtag#PreventiveCare hashtag#AmericanDiabetesAssociation hashtag#ADA
๐๐ฎ๐๐ ๐๐ฒ๐ฒ๐ธ ๐๐ฒ ๐ฐ๐ฒ๐น๐ฒ๐ฏ๐ฟ๐ฎ๐๐ฒ๐ฑ ๐๐ป๐๐ฒ๐ฟ๐ป๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ช๐ผ๐บ๐ฒ๐ปโ๐ ๐๐ฎ๐, ๐ฎ๐ป ๐ผ๐ฝ๐ฝ๐ผ๐ฟ๐๐๐ป๐ถ๐๐ ๐๐ผ ๐ฐ๐ฒ๐น๐ฒ๐ฏ๐ฟ๐ฎ๐๐ฒ ๐๐ผ๐บ๐ฒ๐ป - ๐ฎ๐ป๐ฑ ๐๐ผ ๐ฟ๐ฎ๐ถ๐๐ฒ ๐ฎ๐๐ฎ๐ฟ๐ฒ๐ป๐ฒ๐๐ ๐ฎ๐ฏ๐ผ๐๐ ๐๐ผ๐บ๐ฒ๐ปโ๐ ๐ต๐ฒ๐ฎ๐น๐๐ต.
Did you know that nearly 20 million women in the U.S. are living with diabetes? Diabetes can lead to many serious health complications, including diabetic retinopathy, one of the leading causes of preventable vision loss.
Early detection is key - thatโs why we developed AEYE-DS, the only FDA-cleared autonomous AI solution for point-of-care diabetic retinopathy screening that works with a portable camera and performs a 1-minute eye exam using just one image per eye, helping ensure patients receive timely follow-up care.
Supporting womenโs health means protecting their vision - because awareness and early detection save sight.
๐ก Contact us to learn more - https://t.co/yZNR9y0Ho5
๐ง๐ต๐ฒ ๐๐ป๐ฑ ๐ผ๐ณ ๐๐ต๐ฒ ๐๐น๐ผ๐ผ๐ฑ ๐ฃ๐ฟ๐ฒ๐๐๐๐ฟ๐ฒ ๐๐๐ณ๐ณ? ๐๐ผ๐ ๐๐๐ฌ๐โ๐ ๐๐ ๐ณ๐ผ๐ฟ ๐ฟ๐ฒ๐๐ถ๐ป๐ฎ๐น ๐ถ๐บ๐ฎ๐ด๐ฒ๐ ๐ฅ๐ฒ๐ฑ๐ฒ๐ณ๐ถ๐ป๐ฒ๐ ๐๐ฎ๐ฟ๐ฑ๐ถ๐ผ๐๐ฎ๐๐ฐ๐๐น๐ฎ๐ฟ ๐ ๐ผ๐ป๐ถ๐๐ผ๐ฟ๐ถ๐ป๐ด
We are proud to share that our latest research has been published in BMJ Innovations. The study demonstrates that our AI technology can estimate blood pressure from a single non-mydriatic fundus image (a simple retinal scan) with accuracy comparable, and even slightly superior to conventional arm cuff measurements, featuring greater consistency and stability. This was done with a large validation dataset comparing the AIโs analysis to multiple cuff measurements.
This publication marks a major milestone in demonstrating our technologyโs potential to enable a non-invasive, rapid 1-minute cardiovascular assessment without a cuff.
๐๐ฒ๐ ๐ง๐ฎ๐ธ๐ฒ๐ฎ๐๐ฎ๐๐:
๐ก๐ผ๐ป-๐ฐ๐ผ๐ป๐๐ฎ๐ฐ๐ ๐ฆ๐ฐ๐ฟ๐ฒ๐ฒ๐ป๐ถ๐ป๐ด -ย A rapid,1-minute cardiovascular assessment without a cuff.
๐๐ฎ๐ฟ๐น๐ ๐๐ป๐๐ฒ๐ฟ๐๐ฒ๐ป๐๐ถ๐ผ๐ป -ย Assessing blood pressure and detecting hypertension risk before significant systemic damage occurs.
๐๐ฒ๐๐ผ๐ป๐ฑ ๐๐๐ฒ ๐๐ถ๐๐ฒ๐ฎ๐๐ฒ - Expanding the role of retinal imaging for systemic health assessments.
This study also highlights a key research capability of ๐๐๐ฌ๐-๐ซ - our comprehensive AI diagnostic screening solution, designed to detect a broad range of diseases, currently supporting a wide range of medical indications, and further validating the potential of a routine eye exam to provide meaningful insight into a patientโs both short and long-term cardiovascular health.
**AEYE-X, unlike AEYE-DS, is currently not offered for diagnostic purposes in the U.S.
Read the full press release: https://t.co/U5Jv3Oey0X
๐๐ฒ๐ฏ๐ฟ๐๐ฎ๐ฟ๐ ๐ถ๐ ๐๐ผ๐ ๐ฉ๐ถ๐๐ถ๐ผ๐ป ๐๐๐ฎ๐ฟ๐ฒ๐ป๐ฒ๐๐ ๐ ๐ผ๐ป๐๐ต
Low vision often develops silently, and many patients are unaware until significant damage has occurred. Early detection is critical, especially for diabetic eye disease, the leading cause of blindness in the working-age population. Timely screening can prevent vision loss and protect quality of life.
AEYE-DS enables accurate retinal screening directly in the point of care - such as a primary care setting - helping clinicians identify referable diabetic retinopathy earlier and faster. It is the only FDA-cleared autonomous AI solution that requires just one image per eye and is compatible with a portable camera, enabling expanded access to screening and making it easier and more accessible to enable earlier intervention and prevent loss of vision!